Choosing to invest in a company with a broad focus is one of the smartest things investors can do to achieve financial success. In addition to having a varied portfolio of companies, you can also have individual companies with a varied focus. This provides even greater protection over the long haul.
One of my favorite companies offering a variety in the biotech industry is Vertex (VRTX). At around $38, the company is a reasonable investment and offers everything you could want in a biotech stock. It offers reliable earnings from products that are approved and on the market and it has a healthy pipeline. The company is a true standout and there are several specific things I like about it.
One of the best things about Vertex is the fact it already has two successful drugs on the market. Kalydco is a prescription medicine used for the treatment of cystic fibrosis. The treatment focuses on a small niche in the medical market, but it is the only option of its kind in this niche. The other drug, Incevik is a prescription medicine used in conjunction with two other medicines, peginterferon alfa and ribavirin to treat chronic hepatitis C infections. Vertex is also responsible for a third medication, Lexiva, which was co-discovered with GlaxoSmithKline, is a protease inhibitor used in the treatment of HIV.
In addition to these three drugs, there are eight different drugs in the company’s pipeline. To continue reading, click here.